NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $172.12
  • Forecasted Upside: 19.27 %
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 15 Buy Ratings
  • 0 Strong Buy Ratings
$144.31
▲ +1.21 (0.85%)
1 month | 3 months | 12 months
Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$172.12
▲ +19.27% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $172.12, with a high forecast of $233.00 and a low forecast of $113.00. The average price target represents a 19.27% upside from the last price of $144.31.
Buy
The current consensus among 17 polled investment analysts is to buy stock in Jazz Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 16 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2020Wells Fargo & CompanyBoost Price TargetOverweight$171.00 ➝ $184.00High
i
11/3/2020Royal Bank of CanadaBoost Price TargetOutperform$170.00 ➝ $180.00High
i
11/3/2020BarclaysBoost Price TargetOverweight$225.00 ➝ $233.00High
i
11/3/2020SVB LeerinkBoost Price TargetOutperform$194.00 ➝ $202.00High
i
11/3/2020HC WainwrightBoost Price TargetBuy$185.00 ➝ $195.00High
i
10/26/2020BarclaysBoost Price TargetOverweight$205.00 ➝ $225.00Low
i
10/20/2020TruistBoost Price Target$157.00 ➝ $175.00Medium
i
10/9/2020Jefferies Financial GroupBoost Price TargetBuy$151.00 ➝ $188.00Low
i
10/9/2020SVB LeerinkBoost Price TargetOutperform$164.00 ➝ $182.00Low
i
10/9/2020HC WainwrightBoost Price TargetBuy$175.00 ➝ $185.00Low
i
9/14/2020Royal Bank of CanadaBoost Price Target$160.00 ➝ $170.00Low
i
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$175.00Medium
i
9/14/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$128.00Medium
i
8/13/2020Wells Fargo & CompanyBoost Price TargetOverweight$150.00 ➝ $171.00Low
i
8/6/2020BarclaysReiterated RatingBuyHigh
i
8/6/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$177.00High
i
7/30/2020OppenheimerInitiated CoverageOutperformHigh
i
7/28/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
i
7/23/2020HC WainwrightUpgradeNeutral ➝ Buy$145.00 ➝ $166.00Medium
i
6/23/2020BarclaysBoost Price TargetOverweight$183.00 ➝ $195.00Low
i
6/18/2020Bank of AmericaBoost Price TargetBuy$165.00 ➝ $167.00Low
i
6/1/2020SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $169.00Low
i
5/6/2020SunTrust BanksLower Price TargetBuy$155.00 ➝ $153.00Medium
i
5/6/2020OppenheimerReiterated RatingBuy$132.00Medium
i
5/6/2020SVB LeerinkLower Price TargetOutperform$169.00 ➝ $160.00Medium
i
5/6/2020BMO Capital MarketsLower Price TargetPositive ➝ Outperform$205.00 ➝ $193.00High
i
5/6/2020Piper SandlerLower Price TargetNeutral$127.00 ➝ $113.00High
i
4/30/2020Wells Fargo & CompanyLower Price TargetOverweight$189.00 ➝ $162.00Low
i
4/30/2020OppenheimerLower Price TargetOutperform$154.00 ➝ $141.00Low
i
4/6/2020Jefferies Financial GroupInitiated CoverageBuy$149.00High
i
4/2/2020Morgan StanleyLower Price TargetEqual Weight$147.00 ➝ $109.00Medium
i
3/30/2020Royal Bank of CanadaLower Price Target$164.00 ➝ $174.00Medium
i
3/23/2020Bank of AmericaLower Price TargetBuy$178.00 ➝ $163.00High
i
3/12/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$175.00 ➝ $166.00High
i
2/27/2020SunTrust BanksLower Price TargetBuy$171.00 ➝ $166.00High
i
2/26/2020OppenheimerLower Price Target$183.00 ➝ $154.00High
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
2/26/2020Piper SandlerLower Price Target$142.00 ➝ $129.00High
i
2/26/2020BMO Capital MarketsLower Price TargetOutperform$208.00 ➝ $205.00High
i
2/26/2020Royal Bank of CanadaReiterated RatingOutperform$164.00High
i
2/26/2020CowenLower Price TargetOutperform$200.00 ➝ $165.00High
i
2/26/2020JPMorgan Chase & Co.Boost Price TargetOverweight$173.00 ➝ $183.00High
i
1/31/2020SunTrust BanksReiterated RatingBuy$166.00 ➝ $171.00Low
i
1/22/2020Wells Fargo & CompanyBoost Price TargetOverweight$186.00 ➝ $189.00Low
i
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$153.00Medium
i
12/3/2019Wells Fargo & CompanyBoost Price TargetOutperform$168.00 ➝ $186.00High
i
Rating by David Maris at Wells Fargo & Company
12/2/2019BarclaysBoost Price TargetOverweight$182.00 ➝ $200.00Low
i
Rating by Balaji Prasad at Barclays PLC
11/11/2019HC WainwrightReiterated RatingHold$147.00Medium
i
11/11/2019Evercore ISIReiterated RatingBuyMedium
i
Rating by Umer Raffat at Evercore ISI
11/7/2019BarclaysReiterated RatingBuy$182.00Medium
i
Rating by Balaji Prasad at Barclays PLC
10/14/2019Sanford C. BernsteinReiterated RatingMarket Perform$150.00Low
i
9/26/2019OppenheimerSet Price TargetBuy$176.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
8/21/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$205.00 ➝ $142.00High
i
Rating by David Amsellem at Piper Jaffray Companies
8/14/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
8/12/2019Evercore ISIReiterated RatingBuyMedium
i
Rating by Umer Raffat at Evercore ISI
8/8/2019HC WainwrightReiterated RatingHold$147.00Low
i
8/7/2019BarclaysBoost Price TargetOverweight$164.00 ➝ $180.00High
i
Rating by Balaji Prasad at Barclays PLC
7/8/2019OppenheimerSet Price TargetBuy$176.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
7/3/2019Royal Bank of CanadaSet Price TargetBuy$184.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
7/3/2019BarclaysSet Price TargetBuy$164.00Low
i
Rating by Balaji Prasad at Barclays PLC
7/3/2019BMO Capital MarketsSet Price TargetBuy$208.00Low
i
Rating by Gary Nachman at BMO Capital Markets
7/3/2019MizuhoSet Price TargetHold$148.00Low
i
Rating by Irina Rivkind Koffler at Mizuho
6/17/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$164.00Low
i
5/28/2019Piper Jaffray CompaniesSet Price TargetBuy$202.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
5/10/2019HC WainwrightReiterated RatingHold$153.00Low
i
Rating by O. Livnat at HC Wainwright
5/8/2019MizuhoBoost Price TargetNeutral$146.00 ➝ $148.00High
i
5/8/2019BMO Capital MarketsBoost Price TargetOutperform$206.00 ➝ $208.00High
i
3/27/2019MizuhoReiterated RatingNeutral ➝ Hold$137.00 ➝ $147.00Medium
i
3/26/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$163.00Medium
i
3/19/2019Wells Fargo & CompanySet Price TargetBuy$162.00Low
i
Rating by David Maris at Wells Fargo & Company
3/18/2019Royal Bank of CanadaSet Price TargetBuy$184.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
3/8/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $135.00Medium
i
Rating by David Risinger at Morgan Stanley
2/27/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$199.00 ➝ $206.00Medium
i
2/26/2019Cantor FitzgeraldSet Price TargetBuy$185.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
2/13/2019CowenReiterated RatingBuy$200.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
2/12/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
1/4/2019Cantor FitzgeraldSet Price TargetBuy$201.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
12/23/2018Wells Fargo & CompanyReiterated RatingBuyMedium
i
Rating by David Maris at Wells Fargo & Company
12/23/2018OppenheimerSet Price TargetBuy$180.00Medium
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
12/14/2018Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
i
12/11/2018OppenheimerInitiated CoverageBuy$180.00 ➝ $180.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
11/28/2018Morgan StanleySet Price TargetHold$168.00Low
i
Rating by David Risinger at Morgan Stanley
11/20/2018MizuhoLower Price TargetNeutral$157.00Low
i
11/14/2018HC WainwrightReiterated RatingHold$161.00Medium
i
Rating by Oren Livnat at HC Wainwright
11/8/2018B. RileyLower Price TargetBuy ➝ Buy$219.00 ➝ $190.00Medium
i
11/7/2018CowenSet Price TargetBuy$200.00High
i
Rating by Ken Cacciatore at Cowen Inc
11/7/2018Wells Fargo & CompanyReiterated RatingBuyHigh
i
Rating by David Maris at Wells Fargo & Company
11/7/2018Royal Bank of CanadaSet Price TargetBuy$184.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
11/7/2018Piper Jaffray CompaniesSet Price TargetBuy$208.00High
i
Rating by David Amsellem at Piper Jaffray Companies
11/6/2018Cantor FitzgeraldReiterated RatingBuy$201.00High
i
Rating by William Tanner at Cantor Fitzgerald
10/19/2018Piper Jaffray CompaniesSet Price TargetBuy$213.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
10/15/2018MizuhoReiterated RatingNeutral$173.00High
i
8/17/2018SVB LeerinkBoost Price TargetOutperform$200.00 ➝ $210.00Low
i
8/15/2018Wells Fargo & CompanyReiterated RatingBuy$182.00 ➝ $195.00Medium
i
Rating by David Maris at Wells Fargo & Company
8/9/2018HC WainwrightReiterated RatingHold$167.00Low
i
Rating by Oren Livnat at HC Wainwright
8/9/2018Seaport Global SecuritiesReiterated RatingBuy$207.00Low
i
Rating by Corey Davis at Seaport Global Securities
8/8/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$201.00 ➝ $206.00Medium
i
8/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$180.00 ➝ $205.00High
i
8/8/2018Piper Jaffray CompaniesReiterated RatingBuy$213.00High
i
8/7/2018Cantor FitzgeraldSet Price TargetBuy$203.00High
i
Rating by William Tanner at Cantor Fitzgerald
7/13/2018Evercore ISIReiterated RatingBuyLow
i
Rating by Umer Raffat at Evercore ISI
7/11/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$183.00Low
i
Rating by David Risinger at Morgan Stanley
7/10/2018CitigroupBoost Price TargetBuy ➝ Buy$162.00 ➝ $205.00Low
i
7/8/2018Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
7/2/2018Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
6/26/2018B. RileyBoost Price TargetBuy ➝ Buy$211.00 ➝ $219.00Low
i
6/1/2018Royal Bank of CanadaSet Price TargetBuy$194.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
5/15/2018Wells Fargo & CompanySet Price TargetOutperform$176.00 ➝ $182.00Low
i
Rating by David Maris at Wells Fargo & Company
5/10/2018B. RileyBoost Price TargetBuy ➝ Buy$206.00 ➝ $211.00Medium
i
5/9/2018MizuhoReiterated RatingHold$150.00High
i
5/9/2018HC WainwrightSet Price TargetHold$160.00Low
i
Rating by Oren Livnat at HC Wainwright
5/9/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$199.00 ➝ $201.00Medium
i
4/30/2018Cantor FitzgeraldReiterated RatingBuy$202.00High
i
4/6/2018Seaport Global SecuritiesSet Price TargetBuy$175.00Low
i
Rating by Corey Davis at Seaport Global Securities
3/23/2018HC WainwrightReiterated RatingNeutral$150.00 ➝ $160.00Medium
i
Rating by C. Davis at HC Wainwright
3/19/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$128.58 ➝ $163.75High
i
Rating by David Risinger at Morgan Stanley
3/1/2018Piper Jaffray CompaniesReiterated RatingBuy$201.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
2/28/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$196.00 ➝ $199.00High
i
2/20/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$164.00 ➝ $170.00Low
i
1/16/2018B. RileyReiterated RatingBuy$206.00Low
i
1/16/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$170.00Medium
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$180.00Low
i
Rating by A. Fadia at SVB Leerink LLC
12/25/2017Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
12/20/2017B. RileyReiterated RatingBuy$206.00Low
i
12/10/2017Cantor FitzgeraldReiterated RatingBuy$200.00Low
i
12/5/2017B. RileyReiterated RatingBuy$206.00Low
i
12/5/2017MizuhoBoost Price TargetNeutral ➝ Neutral$144.00 ➝ $150.00Low
i
12/3/2017Cantor FitzgeraldReiterated RatingBuy$200.00Low
i
11/10/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$144.00 ➝ $150.00N/A
i
Rating by C. Davis at HC Wainwright
11/8/2017UBS GroupLower Price TargetBuy$172.00 ➝ $168.00N/A
i
11/8/2017Wells Fargo & CompanyReiterated RatingOutperform$177.00 ➝ $172.00N/A
i
Rating by David Maris at Wells Fargo & Company
11/8/2017Royal Bank of CanadaLower Price TargetOutperform$210.00 ➝ $195.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
11/8/2017Royal Bank of CanadaReiterated RatingOutperform$210.00 ➝ $195.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/26/2017Stifel NicolausReiterated RatingBuy$190.00N/A
i
10/23/2017CowenSet Price TargetBuy$190.00N/A
i
Rating by Ken Cacciatore at Cowen Inc
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$177.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
10/19/2017FBR & CoInitiated CoverageBuy ➝ Buy$206.00N/A
i
Rating by D. Buck at FBR & Co
10/5/2017Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$155.00N/A
i
9/28/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$165.00Low
i
9/25/2017UBS GroupReiterated RatingBuy$175.00 ➝ $172.00Low
i
Rating by Marc Goodman at UBS Group AG
9/20/2017BMO Capital MarketsReiterated RatingBuy$196.00High
i
9/18/2017JPMorgan Chase & Co.Reiterated RatingBuy$190.00Low
i
9/15/2017Royal Bank of CanadaReiterated RatingBuy$210.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
8/30/2017Stifel NicolausReiterated RatingBuy$190.00Low
i
8/29/2017Cantor FitzgeraldReiterated RatingBuyLow
i
8/29/2017Wells Fargo & CompanyReiterated RatingBuyLow
i
Rating by David Maris at Wells Fargo & Company
8/25/2017HC WainwrightInitiated CoverageNeutral ➝ Neutral$144.00Low
i
Rating by C. Davis at HC Wainwright
8/21/2017CowenSet Price TargetBuy$190.00Low
i
Rating by Ken Cacciatore at Cowen Inc
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$177.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
8/10/2017Wells Fargo & CompanyReiterated RatingOutperform$178.00 ➝ $177.00Low
i
8/9/2017CowenReiterated RatingOutperform$190.00Low
i
Rating by Ken Cacciatore at Cowen Inc
8/9/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$178.00 ➝ $175.00High
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/9/2017Royal Bank of CanadaReiterated RatingBuyLow
i
Rating by Randall Stanicky at Royal Bank of Canada
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 ➝ $192.00Low
i
7/17/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$174.00 ➝ $178.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
7/14/2017Piper Jaffray CompaniesSet Price TargetBuy$182.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
7/14/2017CowenReiterated RatingBuy$190.00Low
i
Rating by Ken Cacciatore at Cowen Inc
7/4/2017MizuhoDowngradeBuy ➝ Neutral$162.00 ➝ $150.00Low
i
7/4/2017SVB LeerinkBoost Price TargetBuy$169.00 ➝ $170.00Low
i
Rating by Jason Gerberry at SVB Leerink LLC
7/4/2017Janney Montgomery ScottBoost Price TargetNeutral ➝ Buy$138.00 ➝ $175.00Low
i
7/4/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$176.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/27/2017Royal Bank of CanadaSet Price TargetBuy$210.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
6/27/2017Cantor FitzgeraldReiterated RatingBuy$197.00Medium
i
Rating by William Tanner at Cantor Fitzgerald
6/12/2017JPMorgan Chase & Co.Reiterated RatingOverweight$190.00Low
i
6/7/2017BMO Capital MarketsBoost Price TargetOutperform$192.00 ➝ $196.00Medium
i
6/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$182.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
6/7/2017CowenReiterated RatingOutperform$190.00Medium
i
Rating by Ken Cacciatore at Cowen Inc
5/31/2017MizuhoLower Price TargetNeutral ➝ Neutral$150.00 ➝ $144.00High
i
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 ➝ $176.00Low
i
5/15/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$210.00Low
i
5/10/2017CowenReiterated RatingOutperform$190.00Low
i
4/27/2017SVB LeerinkSet Price TargetBuy$179.00Low
i
Rating by Jason Gerberry at SVB Leerink LLC
4/27/2017Cantor FitzgeraldReiterated RatingBuyHigh
i
Rating by William Tanner at Cantor Fitzgerald
4/8/2017Piper Jaffray CompaniesSet Price TargetBuy$181.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
4/7/2017Cantor FitzgeraldBoost Price TargetOverweight$189.00 ➝ $197.00Low
i
Rating by William Tanner at Cantor Fitzgerald
4/7/2017CowenReiterated RatingOutperform$190.00Low
i
4/6/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$176.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
4/6/2017UBS GroupSet Price TargetBuy$168.00N/A
i
Rating by Marc Goodman at UBS Group AG
4/6/2017SVB LeerinkSet Price TargetBuy$169.00 ➝ $170.00Low
i
Rating by Jason Gerberry at SVB Leerink LLC
4/6/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$138.00 ➝ $175.00High
i
4/6/2017MizuhoDowngradeBuy ➝ Neutral$162.00 ➝ $150.00High
i
3/21/2017MizuhoReiterated RatingBuy ➝ Buy$152.00 ➝ $162.00Low
i
3/20/2017SVB LeerinkReiterated RatingOutperformLow
i
Rating by Jason Gerberry at SVB Leerink LLC
3/20/2017CowenReiterated RatingOutperform ➝ Positive$190.00High
i
3/20/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$192.00High
i
3/1/2017Cantor FitzgeraldSet Price TargetBuy$187.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
3/1/2017SVB LeerinkSet Price TargetBuy$170.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
3/1/2017Stifel NicolausLower Price TargetBuy$200.00 ➝ $190.00N/A
i
3/1/2017MizuhoReiterated RatingBuy$152.00N/A
i
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/A
i
2/21/2017MizuhoBoost Price TargetBuy ➝ Buy$127.00 ➝ $152.00N/A
i
2/16/2017GuggenheimReiterated RatingBuyN/A
i
Rating by Louise Chen at Guggenheim
2/15/2017BMO Capital MarketsReiterated RatingTop Pick$192.00N/A
i
2/9/2017GuggenheimReiterated RatingBuy ➝ Buy$200.00N/A
i
2/8/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$148.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
1/24/2017Cantor FitzgeraldReiterated RatingOverweight$187.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
1/19/2017SunTrust BanksReiterated RatingBuy$210.00N/A
i
1/19/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$148.00N/A
i
1/18/2017Cantor FitzgeraldSet Price TargetBuy$187.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
1/18/2017SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
1/18/2017The Goldman Sachs GroupReiterated RatingBuy$170.00N/A
i
1/18/2017MizuhoReiterated RatingNeutral$127.00N/A
i
1/18/2017UBS GroupReiterated RatingBuy$168.00N/A
i
Rating by Marc Goodman at UBS Group AG
1/18/2017BarclaysReiterated RatingOverweight$200.00N/A
i
1/12/2017BMO Capital MarketsReiterated RatingOutperform$192.00N/A
i
1/12/2017Cantor FitzgeraldReiterated RatingBuy$187.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$187.00N/A
i
11/9/2016UBS GroupSet Price TargetBuy$168.00N/A
i
Rating by Marc Goodman at UBS Group AG
11/9/2016SVB LeerinkSet Price TargetBuy$182.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
11/9/2016BMO Capital MarketsLower Price TargetOutperform$195.00 ➝ $192.00N/A
i
11/9/2016MizuhoLower Price TargetBuy$185.00 ➝ $127.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/28/2016SVB LeerinkSet Price TargetBuy$178.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
10/7/2016BMO Capital MarketsReiterated RatingOutperform$195.00N/A
i
9/27/2016The Goldman Sachs GroupReiterated RatingBuy$195.00 ➝ $187.00N/A
i
Rating by Gary Nachman at The Goldman Sachs Group, Inc.
9/20/2016UBS GroupSet Price TargetBuy$168.00N/A
i
Rating by marc goodman at UBS Group AG
9/15/2016MizuhoReiterated RatingBuy$185.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/8/2016BMO Capital MarketsReiterated RatingOutperform$193.00 ➝ $195.00N/A
i
9/7/2016SVB LeerinkReiterated RatingOutperform$202.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
8/25/2016Janney Montgomery ScottInitiated CoverageNeutralN/A
i
8/11/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$155.00 ➝ $158.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/11/2016SVB LeerinkReiterated RatingBuy$202.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
8/11/2016The Goldman Sachs GroupReiterated RatingBuy$196.00 ➝ $195.00N/A
i
Rating by Gary Nachman at The Goldman Sachs Group, Inc.
8/10/2016BarclaysReiterated RatingBuy$200.00N/A
i
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$188.00 ➝ $178.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
8/10/2016MizuhoLower Price TargetBuy$195.00 ➝ $185.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/31/2016BMO Capital MarketsReiterated RatingOutperform$190.00N/A
i
7/19/2016MizuhoBoost Price TargetBuy$193.00 ➝ $195.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$190.00N/A
i
6/21/2016MizuhoReiterated RatingBuy$193.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/18/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by David Maris at Wells Fargo & Company
6/17/2016SVB LeerinkReiterated RatingOutperform$200.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
6/6/2016MizuhoReiterated RatingBuyN/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/6/2016Piper Jaffray CompaniesReiterated RatingOverweight$186.00 ➝ $188.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
6/6/2016The Goldman Sachs GroupInitiated CoverageNeutral ➝ Buy$196.00N/A
i
6/2/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/2/2016SunTrust BanksReiterated RatingBuy$200.00 ➝ $210.00N/A
i
Rating by John Boris at SunTrust Banks, Inc.
5/31/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
5/31/2016Piper Jaffray CompaniesReiterated RatingBuy$186.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
5/18/2016SVB LeerinkReiterated RatingBuy$200.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
5/12/2016Piper Jaffray CompaniesReiterated RatingBuy$186.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
5/11/2016UBS GroupBoost Price TargetBuy$162.00 ➝ $168.00N/A
i
Rating by Marc Goodman at UBS Group AG
5/11/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
5/11/2016MizuhoUpgradeNeutral ➝ Buy$137.00 ➝ $193.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
4/25/2016SunTrust BanksUpgradeNeutral ➝ Buy$164.00 ➝ $200.00N/A
i
4/23/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
4/13/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by David Maris at Wells Fargo & Company
4/13/2016MizuhoReiterated RatingHoldN/A
i
Rating by Irina Rivkind Koffler at Mizuho
4/11/2016SVB LeerinkReiterated RatingOutperform$167.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/A
i
Rating by Corey Davis at Canaccord Genuity
4/2/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/A
i
Rating by David Buck at Northland Securities
3/31/2016UBS GroupReiterated RatingBuy$178.00 ➝ $162.00N/A
i
Rating by Marc Goodman at UBS Group AG
3/31/2016SVB LeerinkReiterated RatingOutperform$167.00N/A
i
Rating by Sharon Stein at SVB Leerink LLC
3/31/2016MizuhoReiterated RatingHold$124.00 ➝ $137.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
3/19/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
2/26/2016Northland SecuritiesLower Price TargetOutperform$200.00 ➝ $175.00N/A
i
Rating by David Buck at Northland Securities
2/26/2016SVB LeerinkBoost Price Target$166.00 ➝ $167.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
2/24/2016Northland SecuritiesReiterated RatingBuyN/A
i
Rating by David Buck at Northland Securities
2/24/2016Canaccord GenuityReiterated RatingBuy$170.00N/A
i
2/24/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$167.00 ➝ $155.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
2/24/2016Stifel NicolausLower Price TargetBuy$225.00 ➝ $200.00N/A
i
2/24/2016MizuhoLower Price TargetNeutral$140.00 ➝ $124.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
2/19/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
1/31/2016MizuhoReiterated RatingNeutral$140.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
1/29/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
1/14/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$173.00 ➝ $167.00N/A
i
1/9/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
1/8/2016SVB LeerinkLower Price TargetOutperform$187.00 ➝ $166.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
11/25/2015Sanford C. BernsteinInitiated CoverageMarket Perform$160.00N/A
i
(Data available from 11/24/2015 forward)
Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $144.31
$142.77
$145.15

50 Day Range

MA: $148.20
$140.79
$157.33

52 Week Range

Now: $144.31
$86.88
$158.98

Volume

397,745 shs

Average Volume

681,693 shs

Market Capitalization

$8.04 billion

P/E Ratio

45.52

Dividend Yield

N/A

Beta

1.17